Journal Article

Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways

Wen, Cuifeng, Yan, Kaiyun, Wang, Jiaqi, Wang, Xiaowen

2022

Overview

Background. Chronic heart failure (CHF) is the end stage of cardiac disease with a 5-year mortality rate reaching 50%. Simvastatin is an antioxidant with lipid-lowering effects, which is commonly used to treat CHF. Resistance training is a nondrug treatment for CHF and exerts a positive effect on both the myocardial structure and function. Objective. This study is aimed at exploring the effects and outcomes of simvastatin combined with resistance training on the mitochondrial membrane potential (MMP) of peripheral blood lymphocytes and the Janus kinase/signal transducer and activator of the transcription 3 (JAK/STAT3) signaling pathway in patients with CHF. Methods. One hundred and eleven patients with CHF were allocated to the control group (CNG) (n=55) and intervention group (IG) (n=56) using the random number table method. The CNG received simvastatin treatment only, whereas the IG received simvastatin treatment plus resistance training. Treatment efficacy, diastolic interventricular septal thickness (IVST), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD), MMP fluorescence intensity, JAK mRNA and STAT3 mRNA relative expression levels, serum C-reactive protein (CRP), galectin-3, interleukin-6 (IL-6), N-terminal–probrain natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and heart-type fatty acid-binding protein (H-FABP) levels were compared in both groups. Results. After 6 months of treatment, diastolic IVST, LVDD, and serum levels of CRP, galectin-3, IL-6, NT-proBNP, hs-cTnT, and H-FABP decreased in both groups and were lower in the IG than in the CNG (P<0.05), whereas LVEF, JAK and STAT3 mRNA relative expression levels, and MMP fluorescence intensity of peripheral blood lymphocytes were higher in the IG than in the CNG (P<0.05). Conclusion. Simvastatin combined with resistance training improves heart function and reduces myocardial damage as well as the occurrence of adverse cardiac events compared with simvastatin alone. The mechanism may be related to the increase of expression of MMP, JAK, and STAT3, the regulation of MMP and JAK/STAT3 signaling pathways in peripheral lymphocytes, the alleviation of mitochondrial damage, and the inhibition of inflammatory response.

• Publisher: Hindawi,John Wiley & Sons, Inc,Wiley
• Subject: Blood pressure / C-reactive protein / Cardiac arrhythmia / Cardiac patients / Cardiomyopathy / Cardiovascular disease / Cor pulmonale / Diabetes / Ejection fraction / Enzymes / Fatty acids / Genetic transcription / Heart / Heart failure / Heart Failure - diagnosis / Heart Failure - metabolism / Heart Failure - therapy / Humans / Hypertension / Janus Kinases - metabolism / Kinases / Membrane Potential, Mitochondrial - physiology / Mortality / Mutual fund industry / Natriuretic peptides / Patient compliance / Patient outcomes / Protein binding / Resistance Training / RNA / Signal Transduction / Simvastatin / Simvastatin - therapeutic use / STAT3 Transcription Factor - genetics / Strength training / Stroke Volume / Ventricular Function, Left / Weight training / Weightlifting